RT Journal Article
SR Electronic
T1 LY-CoV1404 potently neutralizes SARS-CoV-2 variants
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.04.30.442182
DO 10.1101/2021.04.30.442182
A1 Kathryn Westendorf
A1 Stefanie Žentelis
A1 Denisa Foster
A1 Peter Vaillancourt
A1 Matthew Wiggin
A1 Erica Lovett
A1 Jörg Hendle
A1 Anna Pustilnik
A1 J. Michael Sauder
A1 Lucas Kraft
A1 Yuri Hwang
A1 Robert W. Siegel
A1 Jinbiao Chen
A1 Beverly A. Heinz
A1 Richard E. Higgs
A1 Nicole Kalleward
A1 Kevin Jepson
A1 Rodrigo Goya
A1 Maia A. Smith
A1 David W. Collins
A1 Davide Pellacani
A1 Ping Xiang
A1 Valentine de Puyraimond
A1 Marketa Ricicova
A1 Lindsay Devorkin
A1 Caitlin Pritchard
A1 Aoise O’Neill
A1 Courtney Cohen
A1 John Dye
A1 Kathleen I. Huie
A1 Catherine V. Badger
A1 Darwyn Kobasa
A1 Jonathan Audet
A1 Joshua J. Freitas
A1 Saleema Hassanali
A1 Ina Hughes
A1 Luis Munoz
A1 Holly C. Palma
A1 Bharathi Ramamurthy
A1 Robert W. Cross
A1 Thomas W. Geisbert
A1 Iliana Lanz
A1 Lisa Anderson
A1 Payal Sipahimalani
A1 Kizzmekia S. Corbett
A1 Lingshu Wang
A1 Eun Sung Yang
A1 Yi Zhang
A1 Wei Shi
A1 Barney S. Graham
A1 John R. Mascola
A1 Tara L. Fernandez
A1 Carl L. Hansen
A1 Ester Falconer
A1 Bryan E. Jones
A1 Bryan C. Barnhart
YR 2021
UL http://biorxiv.org/content/early/2021/04/30/2021.04.30.442182.abstract
AB LY-CoV1404 is a highly potent, neutralizing, SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient approximately 60 days after symptom onset. In pseudovirus studies, LY-CoV1404 retains potent neutralizing activity against numerous variants including B.1.1.7, B.1.351, B.1.427/B.1.429, P.1, and B.1.526 and binds to these variants in the presence of their underlying RBD mutations (which include K417N, L452R, E484K, and N501Y). LY-CoV1404 also neutralizes authentic SARS-CoV-2 in two different assays against multiple isolates. The RBD positions comprising the LY-CoV1404 epitope are highly conserved, with the exception of N439 and N501; notably the binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The breadth of variant binding, potent neutralizing activity and the relatively conserved epitope suggest that LY-CoV1404 is one in a panel of well-characterized, clinically developable antibodies that could be deployed rapidly to address current and emerging variants. New variant-resistant treatments such as LY-CoV1404 are desperately needed, given that some of the existing therapeutic antibodies are less effective or ineffective against certain variants and the impact of variants on vaccine efficacy is still poorly understood.In Brief LY-CoV1404 is a potent SARS-CoV-2-binding antibody that neutralizes all known variants of concern and whose epitope is rarely mutated.HighlightsLY-CoV1404 potently neutralizes SARS-CoV-2 authentic virus and all known variants of concernNo loss of potency against current variantsBinding epitope on RBD of SARS-CoV-2 is rarely mutated in GISAID databaseBreadth of neutralizing activity and potency supports clinical developmentCompeting Interest StatementD.F., P. V., A.P., J.H., J.M.S., R.W.S, J.C., I. H., J. J. F., S. H., H. C. P., B. R., B. A. H., R. W. S., J. C., J. M. S., R. E. H., N. K., and B.E.J. are employees and/or stockholders of Eli Lilly and Company. K.W., S. Z., M.W., E.L., L.K., Y.H., K.J., R.G., M.A.S., D.W.C., D.P., P.X., V.d.P., M.R., L.D., C.P., I.L., L.A., P.S., T.L.F., C.L.H, E.F., and B.C.B are employees and stockholders of AbCellera Biologics Inc. AbCellera Biologics Inc. and National Institutes of Health have filed patent applications related to the work described herein (US Patent Application No. 17/192243 and International Patent Application No. PCT/US21/20843, both titled Anti-Coronavirus Antibodies and Methods of Use).